Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $44.52 million. The enterprise value is -$131.32 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 31.35 million shares outstanding. The number of shares has increased by 53.06% in one year.
| Current Share Class | 31.35M |
| Shares Outstanding | 31.35M |
| Shares Change (YoY) | +53.06% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 6.81% |
| Owned by Institutions (%) | 29.26% |
| Float | 13.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.55 |
| Quick Ratio | 10.43 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.07% and return on invested capital (ROIC) is -36.41%.
| Return on Equity (ROE) | -54.07% |
| Return on Assets (ROA) | -33.30% |
| Return on Invested Capital (ROIC) | -36.41% |
| Return on Capital Employed (ROCE) | -49.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 78 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.19% in the last 52 weeks. The beta is 1.90, so ACRV's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | -85.19% |
| 50-Day Moving Average | 3.35 |
| 200-Day Moving Average | 6.24 |
| Relative Strength Index (RSI) | 32.85 |
| Average Volume (20 Days) | 1,269,430 |
Short Selling Information
The latest short interest is 710,505, so 2.27% of the outstanding shares have been sold short.
| Short Interest | 710,505 |
| Short Previous Month | 887,113 |
| Short % of Shares Out | 2.27% |
| Short % of Float | 5.25% |
| Short Ratio (days to cover) | 2.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.20M |
| Pretax Income | -64.12M |
| Net Income | -80.56M |
| EBITDA | -88.19M |
| EBIT | -89.20M |
| Earnings Per Share (EPS) | -$2.38 |
Full Income StatementBalance Sheet
The company has $179.48 million in cash and $3.65 million in debt, giving a net cash position of $175.84 million or $5.61 per share.
| Cash & Cash Equivalents | 179.48M |
| Total Debt | 3.65M |
| Net Cash | 175.84M |
| Net Cash Per Share | $5.61 |
| Equity (Book Value) | 176.79M |
| Book Value Per Share | 5.66 |
| Working Capital | 164.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$65.67 million and capital expenditures -$2.77 million, giving a free cash flow of -$68.44 million.
| Operating Cash Flow | -65.67M |
| Capital Expenditures | -2.77M |
| Free Cash Flow | -68.44M |
| FCF Per Share | -$2.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |